CABA
Cabaletta Bio, Inc.
Biotechnology · Healthcare · United States
1.51
close · 2026-10-30
value
21
cheaper than peers21
quality
28
stronger fundamentals28
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 1.20× | 72 |
| cash flow yield, 3 years ago | -19.1% | 43 |
| cash flow yield, 2 years ago | -21.2% | 43 |
| earnings yield, 3 years ago | -119.9% | 37 |
| cash flow yield, 1 year ago | -35.3% | 35 |
| earnings yield, 2 years ago | -109.3% | 33 |
| cash flow yield, latest year | -51.7% | 24 |
| earnings yield, 1 year ago | -155.0% | 14 |
| earnings yield, latest year | -139.1% | 13 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| debt to equity | 12.2% | 39 |
| return on equity | -93.2% | 29 |
3 of 4 measures available
Facts
| market cap | $256M |
| free cash flow | -$98.3M |
| employees | 154 |
| first trade | 2019-10-25 |
| next earnings | 2026-08-13 |
| fundamentals updated | 2026-08-14 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -2.10 | -2.34 | -1.65 | -1.81 |
| free cash flow | -$132.3M | -$90.4M | -$54.2M | -$48.8M |
| net income | -$167.9M | -$115.9M | -$67.7M | -$53.0M |
| revenue | $0 | $0 | $0 | $0 |